Core Viewpoint - The article discusses a securities class action against Zynex, Inc. due to allegations of false and misleading statements regarding the company's business practices and financial reporting, with a deadline for investors to seek lead plaintiff status set for April 21, 2026 [1]. Group 1: Allegations Against Zynex - Zynex allegedly shipped products in excess of need, inflating its revenue [1][2] - The company faced scrutiny from insurers, including Tricare, for filing false claims [1][2] - A lawsuit was filed by Travelers against Zynex and its executives, seeking over $23 million in damages for fraudulent claims between 2018 and 2023 [1][2] - Management prioritized aggressive sales strategies over compliance with industry regulations [1][2] - The company was not committed to maintaining a strong internal control environment [1][2] - Order growth was attributed to illegal overbilling practices [1][2] - There is a reasonable likelihood of adverse consequences for Zynex, including removal from insurer networks and federal penalties [1][2] - Positive statements made by the defendants about the company's operations were materially misleading [1][2] Group 2: Financial Impact and Stock Performance - On March 11, 2025, Zynex reported a significant revenue shortfall due to slower payments from payers, leading to a stock price drop of $3.59 per share, or 51.3%, closing at $3.41 per share [1][2] - On July 31, 2025, Zynex acknowledged non-compliance with industry regulations, resulting in a stock decline from $2.23 per share to $1.26 per share, a 45% drop [1][2] Group 3: Legal Proceedings and Investor Actions - The court-appointed lead plaintiff will be the investor with the largest financial interest who directs the litigation on behalf of the class [1][2] - Any member of the class may move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1][2] - Faruqi & Faruqi, LLP encourages individuals with information regarding Zynex's conduct to come forward [1][2]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Zynex between February 25, 2021 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - February 24, 20 ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Zynex (ZYXIQ) To Contact Him Directly To Discuss Their Options If you purchased or acquired Zynex securities between February 25, 2021 to December 15, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- What’s Happening: Br ...

SAN FRANCISCO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against the former top executives of Zynex, Inc., whose common stock traded on the NASDAQ exchange under the symbol “ZYXI” prior to its suspension on Dec. 24, 2025 and subsequently traded over the counter as “ZYXIQ.” The lawsuit, captioned Beidel v. Thomas Sandgaard, et al., No. 1:26-cv-00714, was filed in the U.S. District Court for ...

ATLANTA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Zynex, Inc. (“Zynex” or the “Company”) (OTCMKTS: ZYXIQ). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Zynex’s business, operations, and prospects, including allegations that: (1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, the Company inflated its revenue; and (3) th ...

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Zynex, Inc. for alleged misrepresentations regarding the company's revenue related to a fraudulent overbilling scheme from 2018 to 2023 [4]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased or acquired Zynex securities between February 25, 2021, and December 15, 2025 [1]. - Defendants are accused of making false statements about the company's financial performance, specifically its reported revenue [4]. Group 2: Legal Process - Investors wishing to serve as lead plaintiffs must file necessary documents by April 21, 2026 [3]. - Participation as a lead plaintiff is not required to share in any potential recovery from the lawsuit [3]. Group 3: Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its inception in 1993 [5]. - The firm has a strong reputation, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and recognized in The Legal 500 for sixteen consecutive years [5].

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zynex, Inc. (OTCMKTS: ZYXIQ) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zynex securities between February 25, 2021 and December 15, 2025, both dates ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Zynex between February 25, 2021 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Faruqi ...

Core Insights - Zynex, Inc. has entered into a provider agreement with Humana Inc., effective February 1, 2026, marking a significant partnership for the company in the healthcare sector [1][3] Company Overview - Zynex, founded in 1996, specializes in non-invasive medical devices for pain management, aiming to improve the quality of life for patients suffering from debilitating pain [2][5] - The company offers advanced electrotherapy products, including the NexWave™ device, which is now available to in-network Humana members [2] Partnership Details - The partnership with Humana is expected to expand patient access to Zynex's products, as Humana serves nearly 20 million people across the United States and is a leading provider of Medicare Advantage plans [2][3] - Zynex will participate in various health benefits plans offered or administered by Humana, including Medicare-PPO Plans, HMO Plans, and several state Medicaid plans [3] Agreement Terms - Specific terms of the agreement between Zynex and Humana have not been disclosed [4]

Core Viewpoint - Zynex, Inc. is addressing the federal indictments of two former executives while emphasizing its commitment to integrity and compliance under new leadership [1][2][3]. Company Response to Indictments - The individuals indicted are no longer with Zynex and do not influence current operations. Following the indictments, Thomas Sandgaard was removed as director and Chair of the Board [2]. - Zynex has not faced any criminal or civil charges [2]. Leadership and Compliance Overhaul - Over the past six months, Zynex has completely overhauled its leadership, compliance program, billing practices, and operational controls [3]. - The company is under new leadership and is committed to maintaining high integrity in its business practices with rigorous compliance oversight [3]. Cooperation with Authorities - Zynex has cooperated extensively with the Department of Justice and other regulators while seeking a long-term resolution to ongoing investigations [3]. Bankruptcy Proceedings - The company is currently reorganizing under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division [3]. Commitment to Future Operations - Zynex aims to build trust through transparency, integrity, and compliance while focusing on improving the quality of life for patients suffering from pain and other conditions [4].